These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 11172667)
1. Sickle cell anemia and antisickling agents then and now. Mehanna AS Curr Med Chem; 2001 Feb; 8(2):79-88. PubMed ID: 11172667 [TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148 [TBL] [Abstract][Full Text] [Related]
3. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Oder E; Safo MK; Abdulmalik O; Kato GJ Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087 [TBL] [Abstract][Full Text] [Related]
4. Overview of pathophysiology and rationale for treatment of sickle cell anemia. Rodgers GP Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195 [TBL] [Abstract][Full Text] [Related]
5. Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease. Olubiyi OO; Olagunju MO; Strodel B Molecules; 2019 Dec; 24(24):. PubMed ID: 31842406 [TBL] [Abstract][Full Text] [Related]
6. Recent insights on the medicinal chemistry of sickle cell disease. Dos Santos JL; Chin CM Curr Med Chem; 2011; 18(15):2339-58. PubMed ID: 21517749 [TBL] [Abstract][Full Text] [Related]
7. Pathways of innovation: a history of the first effective treatment for sickle cell anemia. Williams VL Perspect Biol Med; 2004; 47(4):552-63. PubMed ID: 15467177 [TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea therapy: improving the lives of patients with sickle cell disease. Anderson N Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291 [TBL] [Abstract][Full Text] [Related]
12. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383 [TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea in the treatment of sickle-cell anemia. Howard LW; Kennedy LD Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697 [TBL] [Abstract][Full Text] [Related]
14. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells. Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905 [TBL] [Abstract][Full Text] [Related]
15. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling. Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875 [TBL] [Abstract][Full Text] [Related]